Page 3 - Immunologicals Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunologicals ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunologicals Ltd Today - Breaking & Trending Today

India Scrambles to Stem COVID-19 Tide as New Cases Continue to Surge


India Scrambles to Stem COVID-19 Tide as New Cases Continue to Surge
India s response to its new COVID-19 epidemic is going through an inflexion.
Passengers at a bus terminal, amid the ongoing surge in coronavirus cases, in Kanpur, Friday, April 16, 2021. Photo: PTI
Bengaluru: India’s response to its new COVID-19 epidemic is going through an inflexion.
It was most prominent when the government stopped sharing its daily bulletin of adverse events following immunisation.
Next, Brazil’s vaccine regulator Anvisa said Bharat Biotech wasn’t following good manufacturing practices to make Covaxin, the ‘Made in India’ vaccine in the country’s two-vaccine inoculation campaign. Supporters of the government rose in its defence but the presence of problems was unmistakable, calling into question why India’s vaccine regulator didn’t notice them. ....

Madhya Pradesh , Uttar Pradesh , Tirath Singh Rawat , Bloomberg Quint , Narendra Modi , Bharat Immunologicals , Niranjani Akhada , Adar Poonawala , Yogi Adityanath , Haffkine Biopharmaceutical Corp , Serum Institute , Biologicals Ltd , Immunologicals Ltd , Commission India , Bharat Biotech , Prime Minister Narendra Modi , Kumbh Mela , Prime Minister Modi , Chief Minister Tirath Singh Rawat , Chief Minister Yogi Adityanath , Economic Times , Maharashtra Run Haffkine Biopharmaceutical , Breaking Headlines Today , Covid 19 , Covid 19 Pandemic , Kinetics Of Inactivation ,

India Going Through a Spate of U-Turns in Scramble To Stem COVID-19 Tide


India Going Through a Spate of U-Turns in Scramble To Stem COVID-19 Tide
17/04/2021
Bengaluru: India’s response to its new COVID-19 epidemic is going through an inflexion.
It was most prominent when the government stopped sharing its daily bulletin of adverse events following immunisation.
Next, Brazil’s vaccine regulator Anvisa said Bharat Biotech wasn’t following good manufacturing practices to make Covaxin, the ‘Made in India’ vaccine in the country’s two-vaccine inoculation campaign. Supporters of the government rose in its defence but the presence of problems was unmistakable, calling into question why India’s vaccine regulator didn’t notice them. ....

New Delhi , Uttar Pradesh , Madhya Pradesh , Tirath Singh Rawat , Bloomberg Quint , Narendra Modi , Bharat Immunologicals , Niranjani Akhada , Adar Poonawala , Yogi Adityanath , Haffkine Biopharmaceutical Corp , Serum Institute , Biologicals Ltd , Immunologicals Ltd , Commission India , Bharat Biotech , Prime Minister Narendra Modi , Kumbh Mela , Prime Minister Modi , Chief Minister Tirath Singh Rawat , Chief Minister Yogi Adityanath , Economic Times , Maharashtra Run Haffkine Biopharmaceutical , புதியது டெல்ஹி , உத்தர் பிரதேஷ் , மத்யா பிரதேஷ் ,